Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Neoadjuvant FL-101 ± nivolumab in resectable NSCLC
2020-005602-26Phase 2Terminated
- Sponsor
- Flame Biosciences
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of abdakibart in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Flame Biosciences. Primary endpoint: Safety and tolerability of FL-101 monotherapy and FL-101 + nivolumab. Started Jun 2021; status: terminated.
02
Drugs
abdakibart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-005602-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005602-26.